Solid Biosciences Announces FDA Ind Clearance for First-in-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
Solid Biosciences宣佈獲得FDA的臨牀試驗申請批准，這是行業內首個雙途徑給藥基因療法，用於治療弗里德里希共濟失調的神經和心臟表現。
